 Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the New Drugs on the Horizon Oral Plenary Session New Preclinical Data to be Presented on Parallel-lead, Clinical-stage Candidate NVL-655, an ALK-selective Inhibitor Selection of Third Development Candidate NVL-330, a Potential Best-in-Class HER2-selective Inhibitor for Patients with HER2 Exon 20 Insertion-Positive Cancers, and Preclinical Characterization to be Presented Company Plans to Host Conference Call in Conjunction with Data Presentation on October 28, 2022 CAMBRIDGE, Mass. , Sept. 7, 2022 PRNewswire -- Nuvalent, Inc. Nasdaq: NUVL, a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 12 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer NSCLC and other solid tumors during an oral plenary session at the 34th EORTC-NCI-AACR ENA Symposium taking place October 26-28, 2022 in Barcelona, Spain. 